Accompanied MDT (AMDT) - More questions than answers

Leprosy Review

Volumn 73, Issue 4, 2002, Pages 301-307

  Ji, Baohong ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEPROSTATIC AGENT;

EDITORIAL; HUMAN; LEPROSY; LEPROSY CONTROL; PATIENT COMPLIANCE; PRACTICE GUIDELINE; TREATMENT PLANNING; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; LEPROSTATIC AGENTS; LEPROSY; PRACTICE GUIDELINES; SELF ADMINISTRATION; TREATMENT REFUSAL; TUBERCULOSIS, PULMONARY;

EID: 0036952653     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (39)

1. World Health Organization, Guide to eliminate leprosy as a public health problem. First edition. World Health Organization, Geneva, 2000.
2. World Health Organization. The final push strategy to eliminate leprosy as a public health problem. Questions & answers. First edition. World Health Organization, Geneva, 2002.
3. World Health Organization. Report on third meeting of the WHO Technical Advisory Group on Elimination of Leprosy. WHO/CDS/CPE/CEE/2002.29.
4. WHO Study Group. Chemotherapy of leprosy for control programmes. Technical Report Series no. 675. World Health Organization, Geneva, 1982.
5. Sumartojo E. When tuberculosis treatment fails. A social behavioural account of patient adherence. Am Rev Respir Dis, 1993; 147: 1311-1320
6. Sackett DL. Introduction. The magnitude of compliance and noncomplance. In: Sackett DL, Haynes RB (eds) Compliance with therapeutic regimens. The Johns Hopkins University Press, Baltimore and London, 1976.
7. Haynes RB, Tayor DW, Sackett DL (eds) Compliance in health care. The Johns Hopkins University Press, Baltimore and London, 1979.
8. Fox W. Problem of self-administration of drugs, with particular reference to pulmonary tuberculosis. Tubercle, 1958; 39: 269-274.
9. Fox W. Self administration of medicaments. A review of published work and a study of the problems. Bull Int Union Tuberc, 1961; 31: 307-331.
10. Fox W. Ambulatory chemotherapy in a developing country: clinical and epidemiological studies. Adv. Tuberc Res, 1963; 12: 28-149.
11. Ellard GA. Drug compliance in the treatment of leprosy. Lepr Rev, 1981; 52: 201-213.
12. Huikeshoven H. Patient compliance with dapsone administration in leprosy. Int J Lepr, 1981; 49: 228-258.
13. Huikeshoven H. Patient compliance in leprosy control: a necessity in old and new regimens. Int J Lepr, 1985; 53: 474-480.
14. Sbarbaro JA, Johnson S. Tuberculous chemotherapy for recalcitrant outpatients administered directly twice weekly. Am Rev Respir Dis, 1968; 97: 895-903.
15. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet, 1995; 345: 1545-1548.
16. Sbarbaro JA. The nature of man and physician. Am Rev Respir Dis, 1981; 123: 147.
17. Sbarbaro JA. Public health aspects of tuberculosis: supervision of therapy. Clin Chest Med, 1980; 1: 253-263.
18. Ellard GA, Gammon PT, Helmy HS, Rees RJW. Urine tests to monitor the self-administration of dapsone by leprosy patients. Am J Trop Med Hyg 1974; 23: 464-470.
19. Ellard GA, Gammon PT, Harris JM. The application of urine tests to monitor the regularity of dapsone self-administration. Lepr Rev, 1974; 45: 224-234.
20. Ellard GA, Pannikar VK, Jesudasan K, Christian M. Clofazimine and dapsone compliance in leprosy. Lepr Rev, 1988; 59: 205-213.
21. Becx-Bleumink M. Duration of multidrug therapy in paucibacillary leprosy patients; experience in leprosy control programme of the All Africa Leprosy and Rehabilitation Training Centre (ALERT) in Ethiopia. Int J Lepr, 1992; 60: 436-444.
22. Hill AR, Manikal VM, Riska PF. Effectiveness of directly observed therapy (DOT) for tuberculosis. A review of multinational experience reported in 1990-2000. Medicine, 2002; 81: 179-193.
23. World Health Organization. What is DOTS? A guide to understanding the WHO-recommended TB control strategy knows as DOTS. WHO/CDS/TB/99.270. World Health Organization, Geneva, 1999.
24. Ji B. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev, 2001; 72: 3-7.
25. Ji B. Rifampicin resistant leprosy: a review and a research proposal of a pilot study. Lepr Rev, 2002; 73: 2-8.
26. World Health Organization. Treatment of tuberculosis. Guidelines for national programmes. Second edition. WHO/TB/97.220. World Health Organization, Geneva, 1997.
27. Fox W, Ellard G, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis, 1999; 3: S231-279.
28. Frieden T, Sbarbaro JA. The slippery slope to sloopy DOTS. Int J Tuberc Lung Dis, 2002; 6: 371-372.
29. World Health Organization. WHO Expert Committee on Leprosy. Seventh Report. WHO Technical Report Series no.874. World Health Organization, Geneva, 1998.
30. World Health Organzation. An expanded DOTS framework for effective tuberculosis control. WHO/CDS/TB/2002.297. World Health Organization, Geneva, 2002.
31. Mathema B, Pande SB, Jochem K et al. Tuberculosis treatment in Nepal: a rapid assessment of government centers using different types of patient supervision. Int J Tuberc Lung Dis, 2001; 5: 912-919.
32. Pungrassami P, Johnsen SP, Chongsuvivatwong V et al. Practice of directly observed treatment (DOT) for tuberculosis in southern Thailand: comparison between different types of DOT observers. Int J Tuberc. Lung Dis, 2002; 6: 389-395.
33. Daumerie D. Accompanied MDT/DOTs. Leprosy Mailing List 17 June 2002.
34. Walley JD, Amir Khan M, Newell JN, Hussain Khan M. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomized controlled trial in Pakistan. Lancet, 2001; 357: 664-669.
35. Various authors. Direct observation for tuberculosis treatment (correspondence). Lancet, 2001; 358: 420-422.
36. Maher D, van Gorkom JLC, Gondrie PCFM, Raviglione M. Community contribution to tuberculosis care in countries with high tuberculosis prevalence: past, present and future. Int J Tuberc Lung Dis, 1999; 3: 762-768.
37. Khatri GR, Frieden TR. Rapid DOTS expansion in India. Bull WHO, 2002; 80: 457-463.
38. Maher D, Hausler HP, Raviglione MC et al. Tuberculosis care in community care organizations in sub-Saharan Africa: Practice and potential. Int J Tuberc Lung Dis, 1997; 1: 276-283.
39. Volmink J, Matchaba P, Garner P. Directly observed therapy and treatment adherence. Lancet, 2000; 355: 1345-1350.